<p>Santen Pharmaceutical Co., Ltd. announced that its Board of Directors has resolved to cancel 19,800,000 common shares, representing 5.8% of its outstanding shares prior to the cancellation. Following this transaction, the total number of outstanding shares will be 322,268,554, and the number of treasury shares will be 574,377. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Santen Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

SNPHY

<p>Santen Pharmaceutical Co., Ltd. has announced the cancellation of 19.8 million common shares, which accounts for 5.8% of its outstanding shares. After this reduction, the total number of outstanding shares will be 322,268,554, with 574,377 shares remaining in treasury.</p>

Santen Pharmaceutical to Cancel 19.8 Million Shares in Capital Reduction